This study compared outcomes for the zotarolimus-eluting Endeavor stent (END) versus the sirolimus-eluting Cypher stent (CYP) in 2,332 all-comer patients treated for coronary artery disease across 5 PCI centers in Denmark. At 18-month follow-up, the END group had higher rates of the primary composite endpoint of death, heart attack, or revascularization (9.7% vs 4.5%, HR=2.19, p<0.0001) as well as all-cause death (4.4% vs 2.7%, HR=1.61, p=0.035) and target lesion revascularization (6.1%